



This week in therapeutics

	,			
Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Inducible T cell co-stimulator (ICOS)	Cell culture and mouse studies suggest that ICOS-stimulated T helper type 17 (Th17) cells could help treat cancer. In xenograft mice with mesothelin-expressing tumor cells, injection of mesothelin-specific Th17 cells cultured with Icos decreased tumor size compared with injection of mesothelin-specific Th17 cells cultured with the co-stimulatory molecule Cd28. Next steps include developing T cell-based therapies that incorporate the ICOS signal to treat patients with leukemia. SciBX 3(45); doi:10.1038/scibx.2010.1349 Published online Nov. 18, 2010	Patent application filed; licensing status unavailable	Paulos, C.M. et al. Sci. Transl. Med published online Oct. 27, 2010; doi:10.1126/scitranslmed.3000448 Contact: Chrystal M. Paulos, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: paulosc@mail.med.upenn.edu Contact: Carl H. June, same affiliation as above e-mail: cjune@exchange.upenn.edu